Trials / Completed
CompletedNCT01630746
A Randomized, Double-Blind, Multicenter Study to Evaluate the Acid-inhibitory and Dose-response Efficacy of TAK-438 (20 mg, 40 mg) in Patients With Proton Pump Inhibitor (PPI) - Resistant Erosive Esophagitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Takeda · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the acid-inhibitory and dose-response efficacy of TAK-438 (20 mg, 40 mg) in patients with PPI-resistant erosive esophagitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TAK-438 | |
| DRUG | TAK-438 |
Timeline
- Start date
- 2012-07-01
- Primary completion
- 2013-09-01
- Completion
- 2013-09-01
- First posted
- 2012-06-28
- Last updated
- 2014-02-10
Locations
11 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01630746. Inclusion in this directory is not an endorsement.